Icon

Achieve Life Sciences Inc Stock Analysis and Price Target COMMON STOCK | Biotechnology | NSD

stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 5.72

-0.14 (-2.39)%

USD 0.12B

0.02M

USD 19.00(+232.17%)

N/A

Icon

ACHV

Achieve Life Sciences Inc (USD)
COMMON STOCK | NSD
USD 5.72
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.12B

N/A

USD 5.72

Achieve Life Sciences Inc Stock Forecast

USD 19.00
(+232.17%)

Based on the Achieve Life Sciences Inc stock forecast from 1 analysts, the average analyst target price for Achieve Life Sciences Inc is USD 19.00 over the next 12 months. Achieve Life Sciences Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Achieve Life Sciences Inc is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Achieve Life Sciences Inc’s stock price was USD 5.72. Achieve Life Sciences Inc’s stock price has changed by +10.85% over the past week, +45.92% over the past month and +106.50% over the last year.

No recent analyst target price found for Achieve Life Sciences Inc
No recent average analyst rating found for Achieve Life Sciences Inc

Company Overview Achieve Life Sciences Inc

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interac...Read More

1040 West Georgia Street, Vancouver, BC, Canada, V6E 4H1

20

December

USD

USA

Adjusted Closing Price for Achieve Life Sciences Inc (ACHV)

Loading...

Unadjusted Closing Price for Achieve Life Sciences Inc (ACHV)

Loading...

Share Trading Volume for Achieve Life Sciences Inc Shares

Loading...

Compare Performance of Achieve Life Sciences Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ACHV

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Achieve Life Sciences Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +3.96 (+1.14%) USD90.24B 26.31 16.84

ETFs Containing ACHV

Symbol Name ACHV's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Achieve Life Sciences Inc (ACHV) Stock

Based on ratings from 1 analysts Achieve Life Sciences Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 1 buy, sell and hold ratings.

ACHV stock's dividend yield is 2.62%. Our analysis grades ACHV stock's dividend yield at F. This means that ACHV stock's dividend yield is above 51% of the stocks in the Biotechnology sector in the NSD exchange. Based on this ACHV may be a average dividend stock for its sector.

Based on targets from 1 analysts, the average taret price for ACHV is USD 19.00 over the next 12 months. The maximum analyst target price is USD 19 while the minimum anlayst target price is USD 19.

ACHV stock's Price/Earning ratio is 2.80. Our analysis grades ACHV stock's Price / Earning ratio at D-. This means that ACHV stock's Price/Earning ratio is above 39% of the stocks in the Biotechnology sector in the NSD exchange. Based on this ACHV may be fairly valued for its sector

The last closing price of ACHV's stock was USD 5.72.

The most recent market capitalization for ACHV is USD 0.12B.

Based on targets from 1 analysts, the average taret price for ACHV is projected at USD 19.00 over the next 12 months. This means that ACHV's stock price may go up by +232.17% over the next 12 months.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...